Amgen’s Lumakras Falls Short Of Mirati’s Adagrasib In Pancreatic Cancer
Pressure On To Make Most Of Lung Cancer Foothold
The firm’s first-in-class KRAS inhibitor has shown lower objective response rates than Mirati’s rival candidate in a Phase I/II pancreatic cancer study, but experts note that its lung cancer opportunity, where Amgen can build up a considerable lead, is larger.
